<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>molecular tumor board &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/molecular-tumor-board/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Sat, 24 Oct 2026 23:05:42 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.1.3</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>molecular tumor board &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>Global tumor board maps investigational options for glioblastoma with MDM2 and EGFR amplifications</title>
		<link>https://bioengineer.org/global-tumor-board-maps-investigational-options-for-glioblastoma-with-mdm2-and-egfr-amplifications/</link>
		
		<dc:creator><![CDATA[]]></dc:creator>
		<pubDate>Sat, 24 Oct 2026 23:05:42 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[case report]]></category>
		<category><![CDATA[CDKN2A]]></category>
		<category><![CDATA[EGFR]]></category>
		<category><![CDATA[Glioblastoma]]></category>
		<category><![CDATA[immunotherapy]]></category>
		<category><![CDATA[MDM2]]></category>
		<category><![CDATA[MGMT promoter methylation]]></category>
		<category><![CDATA[molecular tumor board]]></category>
		<category><![CDATA[next-generation sequencing]]></category>
		<category><![CDATA[paxalisib]]></category>
		<category><![CDATA[precision oncology]]></category>
		<category><![CDATA[WIN Consortium]]></category>
		<guid isPermaLink="false">https://bioengineer.org/?p=452427</guid>

					<description><![CDATA[A new Oncotarget case report details how the WIN Consortium's international molecular tumor board evaluated investigational EGFR, MDM2, CDK4/6 and immune-based strategies for a 55-year-old man with glioblastoma carrying MDM2 and EGFR amplifications.]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">452427</post-id>	</item>
	</channel>
</rss>
